These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 6245210)

  • 21. Estimation of opioid receptor agonist dissociation constants with beta-chlornaltrexamine, an irreversible ligand which also displays agonism.
    Leff P; Dougall IG
    Br J Pharmacol; 1988 Sep; 95(1):234-40. PubMed ID: 2851350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Opioid activity of a benzomorphan lacking an oxygen atom.
    Goldstein A; Naidu A
    Biochem Pharmacol; 1978 Apr; 27(7):1033-6. PubMed ID: 207286
    [No Abstract]   [Full Text] [Related]  

  • 23. Role of spacer and address components in peptidomimetic delta opioid receptor antagonists related to naltrindole.
    Portoghese PS; Nagase H; MaloneyHuss KE; Lin CE; Takemori AE
    J Med Chem; 1991 May; 34(5):1715-20. PubMed ID: 1851846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 3-Hydroxy-17-aralkylmorphinans as potential opiate receptor-site-directed alkylating agents.
    Portoghese PS; Hanson RN; Telang VG; Winger JL; Takemori AE
    J Med Chem; 1977 Aug; 20(8):1020-4. PubMed ID: 197237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties.
    Portoghese PS; Larson DL; Jiang JB; Caruso TP; Takemori AE
    J Med Chem; 1979 Feb; 22(2):168-73. PubMed ID: 218009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diprenorphine has agonist activity at opioid kappa-receptors in the myenteric plexus of the guinea-pig ileum.
    Traynor JR; Corbett AD; Kosterlitz HW
    Eur J Pharmacol; 1987 May; 137(1):85-9. PubMed ID: 3038579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.
    Jones RM; Hjorth SA; Schwartz TW; Portoghese PS
    J Med Chem; 1998 Dec; 41(25):4911-4. PubMed ID: 9836606
    [No Abstract]   [Full Text] [Related]  

  • 28. A remarkable change of opioid receptor selectivity on the attachment of a peptidomimetic kappa address element to the delta antagonist, natrindole: 5'-[N2-alkylamidino)methyl]naltrindole derivatives as a novel class of kappa opioid receptor antagonists.
    Olmsted SL; Takemori AE; Portoghese PS
    J Med Chem; 1993 Jan; 36(1):179-80. PubMed ID: 8380614
    [No Abstract]   [Full Text] [Related]  

  • 29. Synthesis and biological evaluation of 14-alkoxymorphinans. 22.(1) Influence of the 14-alkoxy group and the substitution in position 5 in 14-alkoxymorphinan-6-ones on in vitro and in vivo activities.
    Lattanzi R; Spetea M; Schüllner F; Rief SB; Krassnig R; Negri L; Schmidhammer H
    J Med Chem; 2005 May; 48(9):3372-8. PubMed ID: 15857143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Narcotic alkylating agents: synthesis, structure and biological activities.
    Frigola J; Colombo A; Mas J; Pares J
    Farmaco Sci; 1988 Apr; 43(4):347-62. PubMed ID: 3203738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delta opioid antagonist activity and binding studies of regioisomeric isothiocyanate derivatives of naltrindole: evidence for delta receptor subtypes.
    Portoghese PS; Sultana M; Nelson WL; Klein P; Takemori AE
    J Med Chem; 1992 Oct; 35(22):4086-91. PubMed ID: 1331455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quaternary naltrexone: evidence for the central mediation of discriminative stimulus effects of narcotic agonists and antagonists.
    Valentino RJ; Herling S; Woods JH; Medzihradsky F; Merz H
    J Pharmacol Exp Ther; 1981 Jun; 217(3):652-9. PubMed ID: 6262493
    [No Abstract]   [Full Text] [Related]  

  • 33. Novel opiates and antagonists. 6. 7-Alkyl-6,7-didehydromorphinans.
    Quick J; Herlihy P; Howes JF
    J Med Chem; 1984 May; 27(5):632-7. PubMed ID: 6716400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of new compounds for opioid activity (1983).
    Woods JH; Winger GD; Medzihradsky F; Smith CB; Katz JL
    NIDA Res Monogr; 1984 Mar; 49():361-7. PubMed ID: 6090918
    [No Abstract]   [Full Text] [Related]  

  • 35. A novel series of potent and selective agonists at the opioid kappa-receptor.
    Costello GF; Main BG; Barlow JJ; Carroll JA; Shaw JS
    Eur J Pharmacol; 1988 Jul; 151(3):475-8. PubMed ID: 2850924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Common anionic receptor site hypothesis: its relevance to the antagonist action of naloxone.
    Kobylecki RJ; Carling RW; Lord JA; Smith CF; Lane AC
    J Med Chem; 1982 Feb; 25(2):116-20. PubMed ID: 6276546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological studies with an alkylating narcotic agonist, chloroxymorphamine, and antagonist, chlornaltrexamine.
    Caruso TP; Larson DL; Portoghese PS; Takemori AE
    J Pharmacol Exp Ther; 1980 Jun; 213(3):539-44. PubMed ID: 6162947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design of peptidomimetic delta opioid receptor antagonists using the message-address concept.
    Portoghese PS; Sultana M; Takemori AE
    J Med Chem; 1990 Jun; 33(6):1714-20. PubMed ID: 2160538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro evaluation of a novel, non-competitive opioid receptor antagonist.
    Davis P; Kramer T; Burks T
    Proc West Pharmacol Soc; 1989; 32():163-6. PubMed ID: 2550940
    [No Abstract]   [Full Text] [Related]  

  • 40. Cyprodime analogues: synthesis and pharmacological evaluation.
    Schmidhammer H; Smith CF; Erlach D; Koch M; Krassnig R; Schwetz W; Wechner C
    Prog Clin Biol Res; 1990; 328():37-40. PubMed ID: 2154795
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.